Low Thrombin Generation in Users of a Contraceptive Containing Estetrol and Drospirenone
Authors:
Open Access
- 13 September 2022
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (1) , 135-143
Abstract
Objective: To compare the impact on thrombin generation of the new combined oral contraceptive containing 15 mg estetrol and 3 mg drospirenone with ethinylestradiol (30 or 20 mcg) associated either with 150 mcg levonorgestrel or with 3 mg drospirenone. Methods: Data were collected from the “E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study” (NCT02957630). Overall, the per-protocol set population included 24 subjects in the ethinylestradiol/levonorgestrel arm, 28 subjects in the ethinylestradiol/drospirenone arm, and 34 subjects in the estetrol/drospirenone arm. Thrombograms and thrombin generation parameters (lag time, peak, time to peak, endogenous thrombin potential, and mean velocity rate index) were extracted for each subject at baseline and after 6 cycles of treatment. Results: After 6 cycles of treatment, ethinylestradiol-containing products arms show a mean thrombogram outside the upper limit of the reference range, that is the 97.5th percentile of all baseline thrombograms. On the other hand, the mean thrombogram of estetrol/drospirenone is within this reference interval. After 6 cycles of treatment, all thrombin generation parameters are statistically less affected by estetrol/drospirenone than ethinylestradiol-containing products. Conclusions: In conclusion, an association of 15 mg estetrol with 3 mg drospirenone does not have an impact on thrombin generation compared with ethinylestradiol-containing products that, either associated with levonorgestrel or drospirenone, are able to increase the production of procoagulant factors and decrease the production of anticoagulant ones, shifting the patient to a prothrombotic state. Ethinylestradiol-containing products thus generate prothrombotic environments contrary to estetrol which demonstrates a neutral profile on hemostasis.Keywords
Funding Information
- QUALIblood s.a
This publication has 53 references indexed in Scilit:
- Norethindrone Acetate 1.0 Milligram and Ethinyl Estradiol 10 Micrograms as an Ultra Low-Dose Oral ContraceptiveObstetrics & Gynecology, 2013
- Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) studyJournal of Thrombosis and Haemostasis, 2009
- Prediction of Recurrent Venous Thromboembolism by Endogenous Thrombin Potential and D-DimerClinical Chemistry, 2008
- Estetrol: A unique steroid in human pregnancyThe Journal of Steroid Biochemistry and Molecular Biology, 2008
- Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombographyThrombosis and Haemostasis, 2007
- Determinants of the APTT‐ and ETP‐based APC sensitivity testsJournal of Thrombosis and Haemostasis, 2005
- The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptivesBJOG: An International Journal of Obstetrics & Gynaecology, 1996
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic diseaseThe Lancet, 1995
- Oral Contraceptives and Cardiovascular DiseaseNew England Journal of Medicine, 1981